Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.

Market Cap	$197.29M	P/E Ratio	NaN
52W High	$2.60	52W Low	$0.63
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	0.0%	52W Position	56.3%
Overall Score	41	Value Score	--
Quality Score	--	Technical Score	41

EPS Current Est	$NA	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TLSA	$1.74	+7.74%	328.63K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TLSA	$1.74	+7.7%	328.63K
3
4
5
6

TLSA

TLSA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Tiziana Life Sciences Ltd Data in Excel

Get Tiziana Life Sciences Ltd Data in Excel